Potential role of endothelial dysfunction in hypertension and proteinuria in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab: a pilot prospective observational study Satoru NiheiKazuki SaitoKenzo Kudo Original Article 17 April 2025 Article: 55
Pharmacokinetics, metabolism, and excretion of [14C]-valemetostat in healthy male participants, and in vitro plasma protein binding Masaya TachibanaNicholas SiebersMalaz A. Abutarif Original Article Open access 10 April 2025 Article: 54
Neurofilament light chain as a marker for neuronal damage: integrating in vitro studies and clinical findings in patients with oxaliplatin-induced neuropathy Nina Lykkegaard GehrChristina MortensenLise Ventzel Original Article Open access 10 April 2025 Article: 53
Evolution of computational techniques against various KRAS mutants in search for therapeutic drugs: a review article Ayesha MehmoodMohammed Ageeli HakamiAbdul Wadood Original Article 07 April 2025 Article: 52
Napabucasin targets resistant triple negative breast cancer through suppressing STAT3 and mitochondrial function Limei YuanYaqing ZhuMei Liu Original Article 02 April 2025 Article: 51
The evaluation of the impact of NUDT15 variants on thiopurine metabolism in Japanese children with acute lymphoblastic leukemia Yoichi TanakaRintaro OnoDaisuke Hasegawa Original Article 01 April 2025 Article: 50
Influence of interleukin-6 on the pharmacokinetics and pharmacodynamics of osimertinib in patients with non-small cell lung cancer Hayato YokotaKazuhiro SatoMasatomo Miura Original Article Open access 29 March 2025 Article: 49
An exposure–safety analysis to support the dosage of the novel AKT inhibitor capivasertib Carlos Fernandez TeruelMarie CullbergDiansong Zhou Original Article Open access 28 March 2025 Article: 48
Effect of repeated bolus and continuous doxorubicin administration on bone and soft tissue concentrations– a randomized study evaluated in a tumour-free porcine model Andrea René JørgensenMats BueMaiken Stilling Original Article Open access 24 March 2025 Article: 47
Population pharmacokinetic analysis of bevacizumab in Japanese cancer patients with proteinuria: a prospective cohort study Takashi MasudaTaro FunakoshiAtsushi Yonezawa Original Article 21 March 2025 Article: 46
Alternative routes of drug administration: exposure of imatinib using different formulations H. B. Fiebrich-WestraO. VisserE. J. Smolders Case Report 20 March 2025 Article: 45
New recommendations for reversal of high-dose methotrexate cytotoxicity with folinic acid Jesper HeldrupArchie BleyerScott Howard Original Article Open access 13 March 2025 Article: 41
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature Carolina LiguoriSimona MagiRiccardo Giampieri Case Report Open access 12 March 2025 Article: 40
Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia Christelle DarsteinDeokyong YoonSherwin K. B. Sy Original Article 28 February 2025 Article: 39
Evaluation of Bruton’s Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL) Aziz OuerdaniBelén ValenzuelaJuan José Perez Ruixo Original Article Open access 28 February 2025 Article: 38
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors Susan C. ScottAnna FaragoChristine L. Hann Original Article 25 February 2025 Article: 37
Model-informed development of a cost-saving dosing regimen for enfortumab vedotin Catharina JP Op ’t HoogAmy RiebornRob ter Heine Original Article Open access 25 February 2025 Article: 36
Real-world pharmacokinetics of trametinib in pediatric low-grade glioma Laurie PagnotIsaline GrangerMichael Philippe Original Article 25 February 2025 Article: 35
Thymine as potential biomarker to predict 5-FU systemic exposure in patients with gastro-intestinal cancer: a prospective pharmacokinetic study (FUUT-trial) Maarten A. HanrathEvi BankenMaarten J. Deenen Original Article Open access 15 February 2025 Article: 34
Dose adjustment strategy for high-dose methotrexate-induced toxicities in pediatric acute lymphoblastic leukemia: based on population PK analysis and exposure-toxicity relationship Ailing CaoYanping GuanDunhua Zhou Original Article 15 February 2025 Article: 33
New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis Frank M. BalisElizabeth RiegerMichael C. Milone Original Article Open access 11 February 2025 Article: 32
Food effect trial of the pharmacokinetics and safety of TQ05105 in healthy Chinese subjects Jun DaiYang ChengYingzi Cui Original Article 10 February 2025 Article: 31
Retraction Note: Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma Hui ZhangYan GuoChao Shang Retraction Note 03 February 2025 Article: 30
Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1) Masaki RiShinsuke IidaHirokazu Nagai Original Article 24 January 2025 Article: 29
HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC Kunihiko FunaishiKakuhiro YamaguchiNoboru Hattori Original Article Open access 24 January 2025 Article: 28
Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406) Anuradha KrishnamurthyHong WangLiza C. Villaruz Original Article 22 January 2025 Article: 27
Dihydropyrimidine enzyme activity and its effect on chemotherapy toxicity: importance of genetic testing Alexia Shamaei ZadehDanielle RobertsJohn L. Villano Correspondence 18 January 2025 Article: 26
Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinoma Marinda MeertensEline L. GiraudAlwin D. R. Huitema Original Article 17 January 2025 Article: 25
A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome Keri R. MaherDanielle ShaferSteven Grant Original Article Open access 17 January 2025 Article: 24
Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer Aburough AbegesahDo-Youn OhDiansong Zhou Original Article Open access 17 January 2025 Article: 23
WT161, a selective HDAC6 inhibitor, decreases growth, enhances chemosensitivity, promotes apoptosis, and suppresses motility of melanoma cells João Marcos Oliveira-SilvaLeilane Sales OliveiraAngel Mauricio Castro-Gamero Original Article 17 January 2025 Article: 22
Targeting on the PI3K/mTOR: a potential treatment strategy for clear cell ovarian carcinoma Kewei ZhengGuanqin JinYu Kang Original Article Open access 10 January 2025 Article: 21
Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study Ching-Yuan ChengWen-Chen ChuangJiunn-Liang Ko Original Article 10 January 2025 Article: 20
Pharmacokinetics, mass balance, and metabolism of [14C]PLB1004, a selective and irreversible EGFR-TKI in humans Donghui LiuQian LiWei Zhao Original Article 07 January 2025 Article: 19
Nanotechnology and nanobots unleashed: pioneering a new era in gynecological cancer management – a comprehensive review Naina KumarMishu Mangla Original Article 04 January 2025 Article: 18
Landscape analysis of adverse events and dose intensity for FDA approved oncology small molecules Keagan P. CollinsDonghua YinRajendar K. Mittapalli Brief Report Open access 04 January 2025 Article: 17
DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancy Paul VilquinYves MedardEvelyne Jacqz-Aigrain Case Report 02 January 2025 Article: 16
Tenuigenin inhibits osteosarcoma growth via CIP2A/PP2A/NF-κB axis Shuo YangShasha LiuZixun Dai Original Article 30 December 2024 Article: 15
Variations in serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment Miki Takenaka SatoTakuya ArakiMari Kogo Original Article Open access 26 December 2024 Article: 14
Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy Tao ZhangWei MuLili Liu Original Article Open access 26 December 2024 Article: 13
Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia Safwat A. MangouraMahmoud H. Abdel-RaheemAbeer M. R. Hussein Original Article Open access 23 December 2024 Article: 12
Evaluation of urinary vanin-1 for the early prediction of cisplatin-induced acute kidney injury during neoadjuvant chemotherapy for esophageal cancer Tomonobu UchinoYuna IwanoYoshiyuki Kagawa Original Article 23 December 2024 Article: 11
Plasma clearance of 5-fluorouracil is more influenced by variations in glomerular filtration rate than by uracil concentration Alice MatheuxLaurine CollasAntonin Schmitt Original Article 19 December 2024 Article: 9
Predictive factors for first dose reduction and interruption of lenvatinib after beginning of the standard dose in Japanese patients with thyroid cancer Kazuma FujitaMitsuji NagahamaMasatomo Miura Original Article 19 December 2024 Article: 8
Absorption, single-dose and steady-state metabolism, excretion, and pharmacokinetics of adagrasib, a KRASG12C inhibitor Lisa RahbaekCornelius CilliersJonathan Q. Tran Original Article 19 December 2024 Article: 7
Intrathecal pemetrexed for leptomeningeal metastases in a patient with ALK-rearranged lung adenocarcinoma: a case report Emelie GezeliusMaria PlanckHeather Wakelee Case Report Open access 17 December 2024 Article: 6
